<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "../../nlm/tax-treatment-NS0.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:tp="http://www.plazi.org/taxpub" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">87</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:A116C711-4C18-5A38-8F1E-5E97753A8A64</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Folia Medica</journal-title>
        <abbrev-journal-title xml:lang="en">FM</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0204-8043</issn>
      <issn pub-type="epub">1314-2143</issn>
      <publisher>
        <publisher-name>Plovdiv Medical University</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3897/folmed.65.e89198</article-id>
      <article-id pub-id-type="publisher-id">89198</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Surgery &amp; Invasive treatment</subject>
          <subject>Women health</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Safety and efficacy of ovarian tissue autotransplantation: A systematic literature review</article-title>
      </title-group>
      <contrib-group content-type="authors">
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Giovannopoulou</surname>
            <given-names>Eirini</given-names>
          </name>
          <email xlink:type="simple">eirini.giovannopoulou@yahoo.com</email>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Karakasi</surname>
            <given-names>Maria-Valeria</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Kouroupi</surname>
            <given-names>Maria</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Giatromanolaki</surname>
            <given-names>Alexandra</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Tsikouras</surname>
            <given-names>Panagiotis</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Pavlidis</surname>
            <given-names>Pavlos</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line content-type="verbatim">Laboratory of Forensic Sciences, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece</addr-line>
        <institution>Democritus University of Thrace</institution>
        <addr-line content-type="city">Alexandroupolis</addr-line>
        <country>Greece</country>
      </aff>
      <aff id="A2">
        <label>2</label>
        <addr-line content-type="verbatim">Department of Pathology, General University Hospital of Alexandroupolis, Alexandroupolis, Greece</addr-line>
        <institution>General University Hospital of Alexandroupolis</institution>
        <addr-line content-type="city">Alexandroupolis</addr-line>
        <country>Greece</country>
      </aff>
      <aff id="A3">
        <label>3</label>
        <addr-line content-type="verbatim">Department of Pathology, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece</addr-line>
        <institution>Democritus University of Thrace</institution>
        <addr-line content-type="city">Alexandroupolis</addr-line>
        <country>Greece</country>
      </aff>
      <aff id="A4">
        <label>4</label>
        <addr-line content-type="verbatim">Department of Obstetrics and Gynecology, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece</addr-line>
        <institution>General University Hospital of Alexandroupolis</institution>
        <addr-line content-type="city">Alexandroupolis</addr-line>
        <country>Greece</country>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p>Corresponding author: Eirini Giovannopoulou, Laboratory of Forensic Sciences, Department of Medicine, Democritus University of Thrace, PC 68100, Alexandroupolis, Greece; Email: <email xlink:type="simple">eirini.giovannopoulou@yahoo.com</email>; Tel.: 0030 6949661171</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>06</month>
        <year>2023</year>
      </pub-date>
      <volume>65</volume>
      <issue>3</issue>
      <fpage>362</fpage>
      <lpage>370</lpage>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/77C2D7C7-D3B0-52EF-AAE5-3FD8832F9084">77C2D7C7-D3B0-52EF-AAE5-3FD8832F9084</uri>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>06</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>09</month>
          <year>2022</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Eirini Giovannopoulou, Maria-Valeria Karakasi, Maria Kouroupi, Alexandra Giatromanolaki, Panagiotis Tsikouras, Pavlos Pavlidis</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>Abstract</label>
        <p>Ovarian tissue autotransplantation is an innovative fertility preservation technique that has provoked ongoing investigations. The purpose of the present study was to assess the safety and reproductive performance of ovarian tissue autotransplantation. This review is conducted according to PRISMA guidelines. Seven studies met the inclusion criteria. A total of 3427 patients underwent ovarian tissue cryopreservation and 205 received an autotransplantation. Tissue retrieval was mainly performed by laparoscopy and only one major complication occurred. Transplantations were predominantly performed by open procedures and data on safety were insufficient. A total of 295 autotransplantations were analyzed, resulting in 104 pregnancies. Sixty-five pregnancies led to live births, while nine were ongoing at that time. A pregnancy rate (<abbrev xlink:title="pregnancy rate" id="ABBRID0EVE">PR</abbrev>) of 50.7% and a live-birth rate (LBR) of 32.7% were observed. Natural conception accounted for 46.3% of live births. No birth deficits were recorded. Ovarian tissue autotransplantation seems to be a safe procedure with acceptable pregnancy rates.</p>
      </abstract>
      <kwd-group>
        <label>Keywords</label>
        <kwd>autologous</kwd>
        <kwd>cryopreservation</kwd>
        <kwd>assisted</kwd>
        <kwd>fertility preservation</kwd>
        <kwd>live birth</kwd>
        <kwd>transplantation</kwd>
        <kwd>reproductive techniques</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <sec sec-type="Citation" id="SECID0EDF">
        <title>Citation</title>
        <p>Giovannopoulou E, Karakasi M-V, Kouroupi M, Giatromanolaki A, Tsikouras P, Pavlidis P. Safety and efficacy of ovarian tissue autotransplantation: A systematic literature review. Folia Med (Plovdiv) 2023;65(3):362-370. doi: <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.3897/folmed.65.e89198">10.3897/folmed.65.e89198</ext-link>.</p>
      </sec>
    </notes>
  </front>
  <body>
    <sec sec-type="Introduction" id="SECID0EPF">
      <title>Introduction</title>
      <p>Fertility preservation (<abbrev xlink:title="Fertility Preservation" id="ABBRID0EVF">FP</abbrev>) has become a field of major interest in the recent years.<sup>[<xref ref-type="bibr" rid="B1 B2 B3">1–3</xref>]</sup> Cancer is the main indication, but several non-oncologic conditions and associated therapies may also have adverse sequelae on future fertility.‌<sup>[<xref ref-type="bibr" rid="B1">1</xref>]</sup> Oocyte and embryo cryopreservation are available for fertility preservation in post-pubertal women.<sup>[<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>]</sup> These are methods dependent on controlled ovarian stimulation (<abbrev xlink:title="controlled ovarian stimulation" id="ABBRID0ESG">COS</abbrev>), a process that necessitates post-pubertal status and adequate time for the procedure to be completed before initiation of gonadotoxic therapy.<sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup></p>
      <p>On the contrary, <abbrev xlink:title="Fertility Preservation" id="ABBRID0E5G">FP</abbrev> procedures independent from controlled ovarian stimulation are the only option in prepubertal status, hormone-dependent malignancies or aggressive tumors, in need for immediate intervention.<sup>[<xref ref-type="bibr" rid="B2">2</xref>]</sup> Ovarian tissue cryopreservation (<abbrev xlink:title="Ovarian Tissue Cryopreservation" id="ABBRID0EJH">OTC</abbrev>) and autotransplantation after thawing has been described as an experimental possibility in the late ‘90s.<sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup> In 2004, the report of the first live birth after ovarian tissue autotransplantation in humans by Donnez et al. encouraged further research.<sup>[<xref ref-type="bibr" rid="B6">6</xref>]</sup></p>
      <p>The classification of <abbrev xlink:title="Ovarian Tissue Cryopreservation" id="ABBRID0E3H">OTC</abbrev> as experimental or established is strongly debated under the light of emerging evidence.‌<sup>[<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B7">7</xref>]</sup> According to the current data, the number of babies born after ovarian tissue transplantation techniques may exceed 200.<sup>[<xref ref-type="bibr" rid="B8">8</xref>]</sup> The purpose of the present study was to review and summarize the current knowledge and experience on ovarian transplantation on 1) fertility outcomes (pregnancy rates, live births, early pregnancy complications) and 2) procedural surgical safety of tissue harvesting and transplantation. A special focus is given to procedure-related complications that are underinvestigated.</p>
    </sec>
    <sec sec-type="materials|methods" id="SECID0EXAAC">
      <title>Materials and methods</title>
      <sec sec-type="Search strategy" id="SECID0E2AAC">
        <title>Search strategy</title>
        <p>The search protocol used in the present study is in accordance with the guidelines for Systematic Reviews and Meta-analyses, as reported in PRISMA.<sup>[<xref ref-type="bibr" rid="B9">9</xref>]</sup> Two reviewers (EG, VK) independently searched medical databases (Pubmed, Clinicaltrials.gov) for eligible studies. Original studies that investigated fertility outcomes (pregnancies, live births) following human ovarian tissue autotransplantation were included in the present study. Studies with fewer than 10 subjects were excluded from the review, as well as studies not written in English language.</p>
      </sec>
      <sec sec-type="Data sources and search strategy" id="SECID0EIBAC">
        <title>Data sources and search strategy</title>
        <p>The Pubmed (1966-2019) and Clinicaltrials.gov were searched for eligible studies. The independent researchers used a standardized search protocol with the following combination of key words: (ovarian tissue transplantation AND pregnancy) OR (ovarian tissue transplantation AND fertility). <bold>Fig. <xref ref-type="fig" rid="F1">1</xref></bold> displays the ‘PRISMA’ flow diagram. The characteristics of the patients and the studied outcomes are listed in <bold>Tables <xref ref-type="table" rid="T1">1</xref>, <xref ref-type="table" rid="T2">2</xref>.</bold></p>
        <fig id="F1" position="float" orientation="portrait">
          <object-id content-type="arpha">3E3E9D7E-9A23-5957-8BBA-208495D87396</object-id>
          <label>Figure 1.</label>
          <caption>
            <p>PRISMA flow diagram.</p>
          </caption>
          <graphic xlink:href="foliamedica-65-3-e89198-g001.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_870437.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/870437</uri>
          </graphic>
        </fig>
        <table-wrap id="T1" position="float" orientation="portrait">
          <label>Table 1.</label>
          <caption>
            <p>Characteristics of the included patients, the procedure and the complications associated with tissue retrieval and transplantation</p>
          </caption>
          <table id="TID0EGQAE" rules="all">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>First author</bold>
                </td>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>Indication for <abbrev xlink:title="Fertility Preservation" id="ABBRID0EMKAE">FP</abbrev> (NOP <abbrev xlink:title="Ovarian Tissue Cryopreservation" id="ABBRID0ERKAE">OTC</abbrev><sup>a</sup>)</bold>
                </td>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>Age at retrieval <sup>b</sup></bold>
                </td>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>NOP OTT<sup>c</sup></bold>
                </td>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>Approach for retrieval</bold>
                </td>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>Surgical procedure</bold>
                </td>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>Complications retrieval</bold>
                </td>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>Approach for transplantation</bold>
                </td>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>Complications transplantation</bold>
                </td>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>Size of transplants</bold>
                </td>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>Location</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1" style="color: #231f20">Schmidt et al. (2011)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Malignancy (393)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA<sup>d</sup></td>
                <td rowspan="1" colspan="1" style="color: #231f20">3%</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">LAP<sup>f</sup> or MLT<sup>g</sup> (11) or LT<sup>h</sup> (1)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">5×5×(1-2) mm</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Ortho<sup>i</sup> (5) Hetero<sup>j</sup> (1) Both<sup>k</sup> (6)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1" style="color: #231f20">Dittrich et al. (2015)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Malignancy (20)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">30.5 (20-37)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">100%</td>
                <td rowspan="1" colspan="1" style="color: #231f20">LAP</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Partial ovariectomy</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NONE</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">3×3×1 mm</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Ortho</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1" style="color: #231f20">Jensen et al. (2015)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Malignancy or benign conditions (41)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">29.8 (9.5-38.7)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">100%</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NONE</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">5×(5-10)×(1-2) mm</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Ortho (15) Hetero (6) Both (20)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1" style="color: #231f20">Rodriguez-Wallberg et al. (2016)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Malignancy or benign conditions (1608)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">2.9%</td>
                <td rowspan="1" colspan="1" style="color: #231f20">LAP</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Unilateral oophorectomy. Ovarian biopsies Both</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Only minor (bleeding)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Ortho  Hetero (1)  Both</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1" style="color: #231f20">Meirow et al. (2016)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Malignancy (20)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">28.8(14-39)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">100%</td>
                <td rowspan="1" colspan="1" style="color: #231f20">LAP</td>
                <td rowspan="1" colspan="1" style="color: #231f20">unilateral or bilateral oophorectomy</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">MLT</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">5×10× (1-2) mm</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Ortho</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1" style="color: #231f20">Jadoul et al. (2017)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Malignancy or benign conditions (545)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">22.3±8.8<sup>e</sup></td>
                <td rowspan="1" colspan="1" style="color: #231f20">3.9%</td>
                <td rowspan="1" colspan="1" style="color: #231f20">LAP or LT</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">5 minor, 1 major (bleeding)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Ortho</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1" style="color: #231f20">Diaz-Garciaz et al. (2018)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Malignancy (800)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">34.3±7.2</td>
                <td rowspan="1" colspan="1" style="color: #231f20">5.5%</td>
                <td rowspan="1" colspan="1" style="color: #231f20">LAP (738) or MLT (32) or LT(30)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">LT (41) LAP (1)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1" style="color: #231f20">Ortho</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1" style="color: #231f20">Overall mean values</td>
                <td rowspan="1" colspan="1" style="color: #231f20">3427</td>
                <td rowspan="1" colspan="1" style="color: #231f20">29.5±7.8</td>
                <td rowspan="1" colspan="1" style="color: #231f20">45%</td>
                <td rowspan="1" colspan="1" style="color: #231f20">LAP 93% MLT 3.6% LT 3.4%</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1" style="color: #231f20">Overall: 0.3% Major: 0.05% Min or: 0.27%</td>
                <td rowspan="1" colspan="1" style="color: #231f20">LAP or MLT 43.2% LT 56.8%</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1" style="color: #231f20">Ortho: 79.1% Hetero: 4.4% Both: 16.5%</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p><sup>a</sup> NOP <abbrev xlink:title="Ovarian Tissue Cryopreservation" id="ABBRID0E5ZAE">OTC</abbrev>: Number of patients that underwent ovarian tissue cryopreservation; <sup>b</sup> Ages are presented as mean either with range inside the parenthesis (range) or with standard deviations (±SD); <sup>c</sup> NOP OTT: Number of patients that underwent ovarian tissue transplantation, as percentage of the total number of patients that received a transplant and was included in the study; <sup>d</sup> NA: Not addressed; <sup>e</sup> The mean age and standard deviation refer to the whole cohort that underwent <abbrev xlink:title="Ovarian Tissue Cryopreservation" id="ABBRID0EK1AE">OTC</abbrev>, not the subgroup of the patients that received autotransplantation; <sup>f</sup> LAP: Laparoscopy; <sup>g</sup> MLT: Minilaparotomy; <sup>h</sup> LT: Laparotomy; <sup>i</sup> ORTHO: Orthotopic autotransplantation; <sup>j</sup> HETERO: Heterotopic transplantation; <sup>k</sup> BOTH: Orthotopic and heterotopic autotransplantation were simultaneously performed.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap id="T2" position="float" orientation="portrait">
          <label>Table 2.</label>
          <caption>
            <p>Fertility outcomes in the population of patients that received ovarian transplants</p>
          </caption>
          <table id="TID0EVDAG" rules="all">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>Author</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>NOP<sup>a</sup> (Re-transplantations)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>CP<sup>b</sup></bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>NOP ART<sup>c</sup></bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Method ART</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Live birth</bold>
                </td>
                <td rowspan="1" colspan="1" style="color: #231f20">
                  <bold>Early pregnancy complications</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Ongoing pregnancy</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Pregnancies</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Schmidt et al.</td>
                <td rowspan="1" colspan="1">12 (5)</td>
                <td rowspan="1" colspan="1">SF</td>
                <td rowspan="1" colspan="1">10</td>
                <td rowspan="1" colspan="1">IVF<sup>d</sup>/ICSI<sup>e</sup></td>
                <td rowspan="1" colspan="1">3</td>
                <td rowspan="1" colspan="1" style="color: #231f20">2 biochemical, 1 miscarriage</td>
                <td rowspan="1" colspan="1">-</td>
                <td rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Dittrich et al.</td>
                <td rowspan="1" colspan="1">20</td>
                <td rowspan="1" colspan="1">SF</td>
                <td rowspan="1" colspan="1">1</td>
                <td rowspan="1" colspan="1">IVF</td>
                <td rowspan="1" colspan="1">4</td>
                <td rowspan="1" colspan="1" style="color: #231f20">1 miscarriage</td>
                <td rowspan="1" colspan="1">4</td>
                <td rowspan="1" colspan="1">9</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Jensen et al.</td>
                <td rowspan="1" colspan="1">41 (12)</td>
                <td rowspan="1" colspan="1">SF</td>
                <td rowspan="1" colspan="1">NA</td>
                <td rowspan="1" colspan="1">IVF</td>
                <td rowspan="1" colspan="1">13 (1 twin)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">9 miscarriage, 2 abortions , 4 biochemical</td>
                <td rowspan="1" colspan="1">1</td>
                <td rowspan="1" colspan="1">28</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Rodriguez-Wallberg et al.</td>
                <td rowspan="1" colspan="1">47 (72)</td>
                <td rowspan="1" colspan="1">SF</td>
                <td rowspan="1" colspan="1">7</td>
                <td rowspan="1" colspan="1">IVF/ICSI</td>
                <td rowspan="1" colspan="1">17</td>
                <td rowspan="1" colspan="1" style="color: #231f20">1 ectopic</td>
                <td rowspan="1" colspan="1">2</td>
                <td rowspan="1" colspan="1">20</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Meirow et al.</td>
                <td rowspan="1" colspan="1">20 (1)</td>
                <td rowspan="1" colspan="1">SF</td>
                <td rowspan="1" colspan="1">14</td>
                <td rowspan="1" colspan="1">IVF</td>
                <td rowspan="1" colspan="1">10 (1 twin)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">1 biochemical , 1 ectopic, 3 miscarriages</td>
                <td rowspan="1" colspan="1">2</td>
                <td rowspan="1" colspan="1">16</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Jadoul et al.</td>
                <td rowspan="1" colspan="1">21</td>
                <td rowspan="1" colspan="1">SF</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">-</td>
                <td rowspan="1" colspan="1">10</td>
                <td rowspan="1" colspan="1" style="color: #231f20">NA</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">10</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Diaz-Garciaz et al.</td>
                <td rowspan="1" colspan="1">44</td>
                <td rowspan="1" colspan="1">SF</td>
                <td rowspan="1" colspan="1">28</td>
                <td rowspan="1" colspan="1">NA</td>
                <td rowspan="1" colspan="1">10</td>
                <td rowspan="1" colspan="1" style="color: #231f20">5</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">15</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TOTAL</td>
                <td rowspan="1" colspan="1">205 (90)</td>
                <td rowspan="1" colspan="1" style="color: #231f20">SF 100%</td>
                <td rowspan="1" colspan="1">&gt;60</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">67 (65 pregnancies , 2 twin gestations)  LBR<sup>e</sup> 32.7%</td>
                <td rowspan="1" colspan="1" style="color: #231f20">30 complications reported (28.8% of total pregnancies) 7 (6.7 %) biochemical,  14 (13.5 %) miscarriages,  2 (1.9%) abortions,  2 (1.9%) ectopic,  5 (4.8%) not classified</td>
                <td rowspan="1" colspan="1">9 (8.7%)</td>
                <td rowspan="1" colspan="1">104 <abbrev xlink:title="pregnancy rate" id="ABBRID0ELFAG">PR</abbrev><sup>f</sup> 50.7%</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p><sup>a</sup> NOP: Number of patients that received a transplant; <sup>b</sup> CP: cryopreservation technique; <sup>c</sup> ART: Assisted Reproduction Technology; <sup>d</sup> IVF: In-vitro fertilization; <sup>d</sup> ICSI: Intracytoplasmic sperm injection; <sup>e</sup> Number of infants born alive, beyond the threshold of viability over 24 weeks of gestational age per patient; <sup>f</sup> Number of pregnancies diagnosed by β-HCG elevation per patient.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec sec-type="Outcomes measures" id="SECID0E5BAC">
        <title>Outcomes measures</title>
        <p>The primary outcome measures were pregnancy rates, live births, and early pregnancy complications associated with ovarian tissue transplantation as well as surgical complications during harvesting and transplantation of the tissue. As secondary outcome measures, the presence of birth deficits, the route of delivery and prematurity were assessed.</p>
      </sec>
    </sec>
    <sec sec-type="Results" id="SECID0EDCAC">
      <title>Results</title>
      <sec sec-type="Excluded studies" id="SECID0EHCAC">
        <title>Excluded studies</title>
        <p>According to the present search protocol, fifteen studies were considered for inclusion in this review. The reviewers assessed all of them for eligibility. Finally, seven studies fulfilled the inclusion criteria for participation in the present analysis. The eligible studies included a total of 3427 patients that underwent ovarian tissue harvesting and cryopreservation for future use. A total of 205 patients had been subjected to ovarian tissue autotransplantation and their outcomes are analyzed in the present review. Four of the included studies were retrospective in design<sup>[<xref ref-type="bibr" rid="B10 B11 B12 B13">10–13</xref>]</sup>, two were prospective non-comparative<sup>[<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>]</sup>, and one was prospective comparative<sup>[<xref ref-type="bibr" rid="B16">16</xref>]</sup> comparing oocyte vitrification to ovarian tissue freezing<sup>[<xref ref-type="bibr" rid="B16">16</xref>]</sup>.</p>
      </sec>
      <sec sec-type="Characteristics of the included patients" id="SECID0ENDAC">
        <title>Characteristics of the included patients</title>
        <p>A total of 3427 patients were subjected to ovarian tissue retrieval and cryostorage for fertility preservation, mainly due to malignancy. Some studies, also, included patients diagnosed with non-oncologic conditions such as hematologic, immunologic/systematic<sup>[<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B13">13</xref>]</sup>, genetic<sup>[<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>]</sup> or benign / borderline ovarian pathology.<sup>[<xref ref-type="bibr" rid="B13">13</xref>]</sup> Mean age of patients was 29.5±7.8 years.</p>
      </sec>
      <sec sec-type="Characteristics of the grafts and the techniques used for tissue retrieval and transplantation (approach, location)" id="SECID0EUEAC">
        <title>Characteristics of the grafts and the techniques used for tissue retrieval and transplantation (approach, location)</title>
        <p>Ovarian tissue was mainly retrieved by laparoscopy (93%). Two studies described ovarian tissue harvesting by laparotomy or minilaparotomy (3.4% and 3.6%, respectively).‌<sup>[<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B16">16</xref>]</sup> Type of surgery for ovarian tissue retrieval varied among partial ovariectomy, unilateral or bilateral oophorectomy and ovarian biopsies. Fewer data are available on the procedure and complications encountered in tissue transplantation. Only three studies report the approach used for transplantation (laparoscopy, minilaparotomy or laparotomy).<sup>[<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>]</sup> Among those providing quantitative data, transplantation was performed in 56.8% by laparotomy and in the remaining 43.2% by laparoscopy or minilaparotomy.‌<sup>[<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>]</sup></p>
        <p>The grafts used for transplantation varied in dimensions, but what was common was a minimum thickness of 1 mm of cortex.<sup>[<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>]</sup> Orthotopic transplantation was the prevalent choice (79.1%).<sup>[<xref ref-type="bibr" rid="B13 B14 B15 B16">13–16</xref>]</sup> Alternatively, both orthotopic and heterotopic transplantations were performed simultaneously (16.5%). Only 8 cases of exclusive heterotopic transplantation are reported in these studies, resulting in 4.4% of the total cases.<sup>[<xref ref-type="bibr" rid="B10 B11 B12">10–12</xref>]</sup> The results are presented in <bold>Table <xref ref-type="table" rid="T1">1</xref></bold>.</p>
      </sec>
      <sec sec-type="Primary outcome measures" id="SECID0ELHAC">
        <title>Primary outcome measures</title>
        <p>As far as ovarian tissue retrieval is concerned, two studies reported no complications during the procedure.<sup>[<xref ref-type="bibr" rid="B10">10</xref>,14]</sup> Rodriquez-Wallberg et al. reported only minor complications (such as minor bleeding) in laparoscopic tissue retrieval.<sup>[<xref ref-type="bibr" rid="B12">12</xref>]</sup> Jadoul et al. described several minor complications such as fever, labial hematoma, urinary infection, bowel irritation, psychological distress and one major complication (bleeding) during the retrieval.<sup>[<xref ref-type="bibr" rid="B13">13</xref>]</sup> The overall complications rate was 0.3%. Data on procedure-related complications are not available regarding ovarian tissue transplantation.</p>
        <p>A total of 295 transplantations are included in the present analysis. Ninety out of the 295 transplantations were re-transplantations due to diminished function of the first transplant, aiming either to ovarian endocrine function restoration or pregnancy. In all included studies, the ovarian tissue autografts were preserved by the slow-freezing technique. In the study of Jadoul et al., no assisted reproduction techniques were used, and all live births recorded constitute natural conceptions.<sup>[<xref ref-type="bibr" rid="B13">13</xref>]</sup> Jensen et al. did not provide sufficient quantitative data on the number of patients that were subjected to assisted reproduction techniques in their population, while Diaz-García et al. did not specify the type of ART technique used.<sup>[<xref ref-type="bibr" rid="B10 B11 B12 B13 B14 B15 B16">10–16</xref>]</sup></p>
        <p>A total of 104 pregnancies were achieved between 295 transplantations. A total of 205 patients received a transplant, leading to a pregnancy rate of 50.7%, including re-transplantations. Sixty-five of them (62.5%) resulted in 67 live births, including two multiple pregnancies (twins), leading to live-birth rate of 32.7%. Nine of them (8.7%) were ongoing by the time the studies were published. The remaining 30 pregnancies (28.8%) did not proceed due to early pregnancy complications or legal termination or unclassified etiology, as presented in <bold>Table <xref ref-type="table" rid="T2">2</xref></bold>. Among six studies that provided sufficient data concerning the origin of pregnancies (ART or natural conception) that resulted in live births, including 242 transplantations, 28 pregnancies or 29 live births (including 1 twin pregnancy) resulted from ART and 25 from natural conception. As a result, ART accounted for 53.7% of live births among these patients, while natural conception - for the rest 46.3%.</p>
      </sec>
      <sec sec-type="Secondary outcome measures" id="SECID0E4IAC">
        <title>Secondary outcome measures</title>
        <p>As far as secondary outcomes are concerned, the data provided by the existing studies are sparse. The prevalence of prematurity among neonates born after ovarian tissue transplantations has not been studied so far. Only two studies provided limited data on prematurity. Among 13 live births, nine of them proceeded to term gestations (69.2%). Birth defects were not recorded. Schmidt et al. provided some insight on the obstetrical outcome of pregnancies after ovarian transplantation. The study reported three term pregnancies, one of which was complicated by preeclampsia.<sup>[<xref ref-type="bibr" rid="B11">11</xref>]</sup> The birth weight was estimated to be from 2600 to 3828 g.</p>
      </sec>
    </sec>
    <sec sec-type="Discussion" id="SECID0EKJAC">
      <title>Discussion</title>
      <p>The aim of the present study was to assess the safety and efficacy of ovarian tissue transplantation, in terms of fertility performance and procedural safety. Safety outcome measures were focused on procedure-related complications. Data on procedure-related complications associated with tissue transplantation are under-reported in the current literature. Overall surgical complication rate for tissue retrieval was 0.3%. Ovarian transplantation was associated with a pregnancy rate of 50.7% and a live birth rate of 32.7% per patient.</p>
      <p>Growing follicles are the most vulnerable to the cytotoxic effects of chemotherapy.<sup>[<xref ref-type="bibr" rid="B17">17</xref>]</sup> The main impact in the ovary is cellular death mediated by apoptosis in primordial follicles, due to the interruption of DNA function.<sup>[<xref ref-type="bibr" rid="B18">18</xref>]</sup> The loss of primordial follicles is irreversible.<sup>[<xref ref-type="bibr" rid="B17">17</xref>]</sup> An alternative hypothesis supports that primordial follicles are exhausted due to their increased recruitment from the “resting pool” secondary to the growing follicles depletion. Nevertheless, indirect effects on the ovary are attributed to decreased vascularization and subsequent ischemia and cortical fibrosis.‌<sup>[<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>]</sup> Ionizing radiotherapy is an important part of cancer therapy.<sup>[<xref ref-type="bibr" rid="B19">19</xref>]</sup> Resting follicles do not demonstrate high mitotic division rates. However, even in that case, the human oocyte is extremely radiosensitive.<sup>[<xref ref-type="bibr" rid="B19">19</xref>]</sup></p>
      <p>Radiation induces histologic changes in the uterus such as endometrial atrophy, myometrial fibrosis, and devascularization.<sup>[<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>]</sup> Apart from the effects on the ovarian reserve and function, the application of high dose radiation during childhood promotes permanent changes to the myometrium and its distensibility, as well as the uterine vasculature.<sup>[<xref ref-type="bibr" rid="B20">20</xref>]</sup> Those changes are associated with a higher risk for complications including implantation/placentation disorders, miscarriage, pretermaturity, and low birth weight, especially in the context of assisted reproduction.<sup>[<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>]</sup></p>
      <p>Chemotherapy has a negative impact on oocyte number and quality and the significance for ovarian tissue cryopreservation before initiation of gonadotoxic therapy has been highlighted, especially in the subgroup of patients aged over 15 years.<sup>[<xref ref-type="bibr" rid="B21 B22 B23 B24">21–24</xref>]</sup> However, this may not be feasible in several clinical scenarios. Nevertheless, the exact impact of chemotherapy (and particular regimens) on fertility outcomes, when applied prior to cryopreservation, has not been fully investigated. There is some evidence that specific non-alkylating agents do not compromise the number of non-growing follicles in biopsies of human ovaries.‌<sup>[<xref ref-type="bibr" rid="B25">25</xref>]</sup> Ovarian tissue cryopreservation is generally not contraindicated, even if a course of chemotherapy has preceded the harvesting of the tissue.<sup>[<xref ref-type="bibr" rid="B26">26</xref>]</sup> The clinical impact of those interventions on post-transplantation fertility outcomes is a field of ongoing research.<sup>[<xref ref-type="bibr" rid="B27">27</xref>]</sup></p>
      <p>In the light of new evidence, the American Society for Reproductive Medicine has removed the label experimental and considers ovarian cryopreservation an acceptable option. However, there is a need for further research, especially concerning the subgroup of pediatric and adolescent populations.<sup>[<xref ref-type="bibr" rid="B28">28</xref>]</sup></p>
      <p>In 2019, Corkum et al. conducted a systematic literature review on fertility preservation after gonadotoxic treatment in this specific subgroup of patients.<sup>[<xref ref-type="bibr" rid="B29">29</xref>]</sup> A total of 1019 patients that underwent <abbrev xlink:title="Ovarian Tissue Cryopreservation" id="ABBRID0EKNAC">OTC</abbrev> were assessed. The median age at retrieval was 19 years and at autotransplantation 24 years and median storage interval was evaluated at 8.7 years. Tissue retrieval was obtained mainly by oophorectomy or alternatively by partial oophorectomy or ovarian biopsies. The procedure was complicated in 3 cases with bleeding. Of cases with major bleeding, one required blood transfusion and another reoperation to surgically achieve hemostasis. Both cases were associated with partial oophorectomy. In all studies that provided relevant data, cryopreservation was carried out with the slow freezing technique. Among 16 patients that sought fertility, a pregnancy rate of 69% and a live-birth rate of 56% was achieved after transplantation. The interesting finding though is that one pregnancy was achieved after OTT of tissue harvested at prepubertal age, and other two pregnancies of tissue harvested at peripubertal age, yet before initiation of menses. All resulted in live births.</p>
      <p>In 2008, Bedaiwy et al. published a systematic review of the literature including case reports and small case series concerning the reproductive outcome after OTT.<sup>[<xref ref-type="bibr" rid="B30">30</xref>]</sup> The authors reported a total of nine pregnancies among 25 patients that received a transplant specifically for fertility restoration (no re-transplantations recorded), leading to 0.36 pregnancies per transplantation/individual, which is comparable to the present findings. The re-transplantations may potentially raise the pregnancy chance, although the true origin of these gestations from the grafted tissue remains hypothetical.</p>
      <p>In 2018, Diaz-Garciaz et al. conducted a prospective study to compare the efficacy of ovarian tissue transplantation versus ovarian oocyte vitrification with 49 patients undergoing OV compared to 44 patients undergoing <abbrev xlink:title="Ovarian Tissue Cryopreservation" id="ABBRID0EZNAC">OTC</abbrev>.<sup>[<xref ref-type="bibr" rid="B16">16</xref>]</sup> The two techniques did not differ significantly on fertility performance. However, a statistically insignificant increase in clinical pregnancy rate and live-birth rate was observed in favor of oocyte vitrification RR 1.31 (95% CI 0.90-1.92) and RR 1.39 (95% CI 0.95-2.03), respectively. Of note, the authors commented that OTT failed to restore fertility in cases where tissue retrieval took place over the age of 36 years. Nevertheless, even in cases where tissue harvesting was performed before that age, no clinical pregnancies were achieved beyond 36 years. On the contrary, oocyte vitrification resulted in a 30% possibility in achieving pregnancy in this subgroup. Diaz-Garciaz described a percentage of 46.7% of natural conception following ovarian tissue transplantation, which is comparable with the present finding of 46.3%.</p>
      <sec sec-type="Future perspectives and fields for future research" id="SECID0EEOAC">
        <title>Future perspectives and fields for future research</title>
        <p>In the clinical setting where controlled ovarian stimulation is not feasible, the possibility of retrieval of immature oocytes (I) from surgical specimens before they are being prepared for cryopreservation)<sup>[<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>]</sup> or (II) with aspiration from the ovaries, as an independent <abbrev xlink:title="Fertility Preservation" id="ABBRID0EVOAC">FP</abbrev> technique<sup>[<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B33 B34 B35">33-35</xref>]</sup> followed by in vitro maturation has arisen. The latter option is also deprived of the surgical complications associated with ovarian tissue grafting and transplantation in non-ovarian malignancies.<sup>[<xref ref-type="bibr" rid="B35">35</xref>]</sup> These oocytes have the potential for in vitro maturation and can, afterwards, be stored as mature oocytes or embryos for use in IVF procedures.<sup>[<xref ref-type="bibr" rid="B36">36</xref>]</sup> A significant advantage of this procedure over ovarian tissue autotransplantation is the elimination of the risk of cancer recurrence by avoiding the transplantation of potentially malignant-contaminated grafts to the host.‌<sup>[<xref ref-type="bibr" rid="B31">31</xref>]</sup> This experimental approach may ‘assist’ ovarian tissue cryopreservation or be applied independently, especially in patients with ovarian malignancies, even in the context of surrogacy.<sup>[<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B37">37</xref>]</sup></p>
        <p>There should be standardization for the ovarian tissue cryopreservation procedures, regarding both the surgical techniques and the specimen preparation for cryobanking, especially in the subgroup of children and adolescents where this is the only fertility preservation option. It has been demonstrated in animal studies that the use of advanced energy devices for tissue retrieval compromises folliculogenesis, compared to cold dissection.<sup>[<xref ref-type="bibr" rid="B38">38</xref>]</sup> Therefore, there are concerns for the effects of thermal energy and thermal spread that should be further investigated. There is evidence that vitrification may have a more favorable impact on ovarian follicles than slow freezing; however, the clinical implications of those findings remain to be determined.<sup>[<xref ref-type="bibr" rid="B39">39</xref>]</sup> This paucity of knowledge highlights the need for optimization of the techniques for tissue processing, including surgical retrieval, graft preparation, graft size and number, and freezing techniques in order to enhance fertility performance after autotransplantation and provide high quality oncofertility care.<sup>[<xref ref-type="bibr" rid="B40">40</xref>]</sup></p>
      </sec>
      <sec sec-type="Strengths and limitations" id="SECID0E5AAE">
        <title>Strengths and limitations</title>
        <p>The literature search was conducted by two independent reviewers. The included studies involve a limited number of patients that were finally submitted to OTT. Interestingly, not all women that received a transplant were seeking fertility. Consequently, the efficacy of OTT in terms of fertility may be underestimated from the inclusion of women that did not desire pregnancy. Nevertheless, there is great heterogeneity among different studies concerning the outcome measures and the number of patients subjected to ART, which is not explicitly stated. Additionally, most studies are lacking information about the obstetrical outcome and complications of pregnancies after OTT. Another concern is the limited follow-up period. Last but not least, data are sparse on prepubertal girls which are a targeted population for the application of the technique. Prolonged cryopreservation and prepubertal status at retrieval may affect reproductive performance, but no sufficient data exist to test this hypothesis.</p>
      </sec>
    </sec>
    <sec sec-type="Conclusions" id="SECID0EDBAE">
      <title>Conclusions</title>
      <p>The present review demonstrates the available data on the safety and efficacy of ovarian tissue transplantation in restoring fertility. The findings of this work support the procedural safety of the technique and confirm an acceptable live-birth rate of 32.7%. However, the absence of randomized clinical trials precluded any sound estimation about the safety and efficacy of the technique in comparison with other <abbrev xlink:title="Fertility Preservation" id="ABBRID0EJBAE">FP</abbrev> options and this is a potential field of future research. More studies are needed to endorse or discourage wide clinical application.</p>
    </sec>
    <sec sec-type="Disclosure of interest" id="SECID0ENBAE">
      <title>Disclosure of interest</title>
      <p>The authors report no conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>This review article is pertinent to the first author’s doctoral dissertation on “Morphometric and histological study of human ovaries in the Greek population” under the documentation code 17/29/07.11.2016 decision of the general assembly of Democritus University of Thrace - Faculty of Medicine.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <mixed-citation xlink:type="simple">1. Nahata L, Woodruff TK, Quinn GP, et al. Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations? J Assist Reprod Genet 2020; 37:1323.</mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation xlink:type="simple">2. Martinez F, Andersen CY, Barri PN, et al. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: Indications, results and future perspectives. Hum Reprod 2017; 32:1802–11.e2.</mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation xlink:type="simple">3. Chae-Kim JJ, Gavrilova-Jordan L. Premature ovarian insufficiency: procreative management and preventive strategies. Biomedicines 2018; 7(1):2.</mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation xlink:type="simple">4. Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. Fertil Steril 2018; 110:380–6.</mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation xlink:type="simple">5. Oktay K, Karlikaya GG, Aydin BA. Ovarian cryopreservation and transplantation: Basic aspects. Mol Cell Endocrinol 2000; 169:105–8.</mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation xlink:type="simple">6. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue.[Erratum appears in Lancet. 2004 Dec 4;364(9450):2020]. Lancet 2004; 364:1405–10.</mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation xlink:type="simple">7. Von Wolff M, Sänger N, Liebenthron J. Is ovarian tissue cryopreservation and transplantation still experimental? It is a matter of female age and type of cancer. J Clin Oncol 2018; 36(33):3340-1.</mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation xlink:type="simple">8. Dolmans M-M, Falcone T, Patrizio P. Importance of patient selection to analyze in vitro fertilization outcome with transplanted cryopreserved ovarian tissue. Fertil Steril 2020; 114:279–80.</mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation xlink:type="simple">9. Moher D, Liberati A, Tetzlaff J, ADPGroup. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. - PubMed - NCBI. PLoS Med 2009; 6(7):e1000097.</mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation xlink:type="simple">10. Jensen AK, Kristensen SG, Macklon KT, et al. Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Hum Reprod 2015; 30(12):2838–45.</mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation xlink:type="simple">11. Tryde Schmidt K, Rosendahl M, Ernst E, et al. Autotransplantation of cryopreserved ovarian tissue in 12 women with chemotherapy-induced premature ovarian failure: the Danish experience. Epub ahead of print 2011. doi: <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.fertnstert.2010.07.1080">10.1016/j.fertnstert.2010.07.1080</ext-link>.</mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation xlink:type="simple">12. Rodriguez-Wallberg KA, Tanbo T, Tinkanen H, et al. Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries – compilation of 20 years of multicenter experience. Acta Obstet Gynecol Scand 2016; 95:1015–26.</mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation xlink:type="simple">13. Jadoul P, Guilmain A, Squifflet J, et al. Efficacy of ovarian tissue cryopreservation for fertility preservation: Lessons learned from 545 cases. Hum Reprod 2017; 32:1046–54.</mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation xlink:type="simple">14. Dittrich R, Hackl J, Lotz L, et al. Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue in a single center. Fertil Steril 2015; 103:462–8.</mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation xlink:type="simple">15. Meirow D, Ra’anani H, Shapira M, et al. Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria. Fertil Steril 2016; 106:467–74.</mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation xlink:type="simple">16. Diaz-Garcia C, Domingo J, Garcia-Velasco JA. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. 109. Epub ahead of print 2018. Doi: <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.fertnstert.2017.11.018">10.1016/j.fertnstert.2017.11.018</ext-link>.</mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation xlink:type="simple">17. Morgan S, Anderson RA, Gourley C, et al. How do chemotherapeutic agents damage the ovary? Hum Reprod Update 2012; 18:525–35.</mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation xlink:type="simple">18. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol 2016; 2333–44.</mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation xlink:type="simple">19. Marci R, Mallozzi M, Di Benedetto L, et al. Radiations and female fertility. Reprod Biol Endocrinol 2018; 16(1):1–2.</mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation xlink:type="simple">20. Teh WT, Stern C, Chander S, et al. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Epub ahead of print 2014. DOI: <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1155/2014/482968">10.1155/2014/482968</ext-link>.</mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation xlink:type="simple">21. Abir R, Ben-Haroush A, Felz C, et al. Selection of patients before and after anticancer treatment for ovarian cryopreservation. Hum Reprod 2008; 23:869–77.</mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation xlink:type="simple">22. Pampanini V, Wagner M, Asadi-Azarbaijani B, et al. Impact of first-line cancer treatment on the follicle quality in cryopreserved ovarian samples from girls and young women. Hum Reprod 2019; 34:1674–85.</mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation xlink:type="simple">23. Meirow D, Dor J, Kaufman B, et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod 2007; 22:1626–33.</mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation xlink:type="simple">24. Wallace WHB, Smith AG, Kelsey TW, et al. Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol 2014; 15:1129–36.</mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation xlink:type="simple">25. McLaughlin M, Kelsey TW, Wallace WHB, et al. Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary. Hum Reprod 2017; 32:165–74.</mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation xlink:type="simple">26. Anderson RA, Amant F, Braat D, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open; 2020. Epub ahead of print October 3, 2020. doi: <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1093/HROPEN/HOAA052">10.1093/HROPEN/HOAA052</ext-link>.</mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation xlink:type="simple">27. Poirot C, Fortin A, Dhédin N, et al. Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies. Haematologica 2019; 104:e360–e3.</mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation xlink:type="simple">28. Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 2019; 112:1022–33.</mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation xlink:type="simple">29. Corkum KS, Rhee DS, Wafford QE, et al. Fertility and hormone preservation and restoration for female children and adolescents receiving gonadotoxic cancer treatments: A systematic review. J Pediatric Surg 2019; 54:2200–9.</mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation xlink:type="simple">30. Bedaiwy MA, El-Nashar SA, El Saman AM, et al. Reproductive outcome after transplantation of ovarian tissue: a systematic review. Hum Reprod 2008; 23(12):2709–17.</mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation xlink:type="simple">31. Segers I, Mateizel I, Van Moer E, et al. In vitro maturation (IVM) of oocytes recovered from ovariectomy specimens in the laboratory: a promising “ex vivo” method of oocyte cryopreservation resulting in the first report of an ongoing pregnancy in Europe. J Assist Reprod Genet 2015; 32(8):1221–31.</mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation xlink:type="simple">32. Huang JYJ, Tulandi T, Holzer H, et al. Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation. Fertil Steril 2008; 89: 567–572.</mixed-citation>
      </ref>
      <ref id="B33">
        <mixed-citation xlink:type="simple">33. Kim SY, Kim SK, Lee JR, et al. Toward precision medicine for preserving fertility in cancer patients: existing and emerging fertility preservation options for women. J Gynecol Oncol 2016;27(2). doi: <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.3802/jgo.2016.27.e22">10.3802/jgo.2016.27.e22</ext-link></mixed-citation>
      </ref>
      <ref id="B34">
        <mixed-citation xlink:type="simple">34. Demirtas E, Elizur SE, Holzer H, et al. Case report: Immature oocyte retrieval in the luteal phase to preserve fertility in cancer patients. Reproductive BioMedicine Online 2008; 17:520–3.</mixed-citation>
      </ref>
      <ref id="B35">
        <mixed-citation xlink:type="simple">35. Huang JYJ, Chian RC, Gilbert L, et al. Retrieval of immature oocytes from unstimulated ovaries followed by in vitro maturation and vitrification: A novel strategy of fertility preservation for breast cancer patients. Am J Surg 2010; 200:177–83.</mixed-citation>
      </ref>
      <ref id="B36">
        <mixed-citation xlink:type="simple">36. Practice Committee of American Society for Reproductive Medicine. Ovarian tissue cryopreservation: A committee opinion. Fertil Steril 2014; 101:1237–43.</mixed-citation>
      </ref>
      <ref id="B37">
        <mixed-citation xlink:type="simple">37. Kim SY, Lee JR. Fertility preservation option in young women with ovarian cancer. Future Oncol 2016; 12:1695–8.</mixed-citation>
      </ref>
      <ref id="B38">
        <mixed-citation xlink:type="simple">38. Rowell EE, Corkum KS, Even KA, et al. Ovarian tissue health after laparoscopic unilateral oophorectomy: A porcine model for establishing optimized fertility preservation techniques in children. J Pediatr Surg 2020; 55:1631–8.</mixed-citation>
      </ref>
      <ref id="B39">
        <mixed-citation xlink:type="simple">39. Shi Q, Xie Y, Wang Y, et al. Vitrification versus slow freezing for human ovarian tissue cryopreservation: a systematic review and meta-analysis. Sci Rep; 7. Epub ahead of print December 1, 2017. Doi: <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1038/S41598-017-09005-7">10.1038/S41598-017-09005-7</ext-link></mixed-citation>
      </ref>
      <ref id="B40">
        <mixed-citation xlink:type="simple">40. Lautz TB, Harris CJ, Laronda MM, et al. A fertility preservation toolkit for pediatric surgeons caring for children with cancer. Semin Pediatr Surg 2019; 28:150861.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
